John Mandeville, PhD
Ophthalmology · East Weymouth, MANPI 1811986060
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,958 of the $2,449 with a category attached, or 80.0%. Amgen accounts for 93.0% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $2,281, more than ten times the $129 reported in 2019.
Across 27 payments — averaging $90.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Kala Pharmaceuticals, Inc.$152
- Tarsus Pharmaceuticals, Inc.$20
Across 1 payment — averaging $12,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$13K
What the payments were for
- Travel & lodging$1,95880%
- Food & beverage$49120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $2,277 |
| Kala Pharmaceuticals, Inc. | 2 | $152 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,449 in reported general payments places this provider in the 70th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 791 | $8,712 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 187 | $2,039 |
| Cephalexin | 321 | $1,517 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 66 | $870 |
| Azithromycin | 72 | $229 |
| Ofloxacin | 17 | $206 |
| Doxycycline Monohydrate | 26 | $188 |
| Alprazolam | 165 | $128 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 15 | $71 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in East Weymouth
- James StefaterEast Weymouth$19K
- Mark DaceyEast Weymouth$17K
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.